This report provides all the information you require to better understand Takeda and its partnering interests and activities over the past seven years.

Takeda Pharmaceuticals is a top pharmaceutical company based in Osaka, Japan

Takeda Pharmaceuticals is a top pharma company active in partnering, licensing and M&A in the pharmaceutical sector

Takeda announced over 115 partnering / licensing deals since 2005, with over84 deals in 2012 alone

Takeda has announced over 10 M&A deals since 2005, with the lead deals being the acquisition of URL Pharma, Millennium and Nycomed

Takeda,  a top pharmaceutical company, is reviewed in terms of partnering, licensing and M&A interests and activity over recent years

In a business merger agreement, Takeda’s wholly-owned subsidiary, Takeda America Holdings, will acquire LigoCyte for an upfront payment of $60 million, with future contingent consideration based on the progress of development projects

Sucampo Pharmaceuticals Inc., the maker of the constipation drug Amitiza, dropped the most in about 3 1/2 years after losing a bid in arbitration to sever ties with marketing partner Takeda Pharmaceutical Co., a top pharma company

Mega merger forms DaVita Healthcare Partners, Bigpharma join forces in search for new antibiotics, and Royalty Pharma raises significant funds for further royalty deals

McKesson lands megadeal for supply of pharmaceuticals to Department of Veterans Affairs

The trend of Japanese pharma making overseas acquisitions continues with Takeda’s M&A deal of URL Pharma for $800 million plus potential follow up payments

Center for iPS Cell Research Application (CiRA) of Kyoto University and Takeda Pharmaceutical will work together to develop clinical applications of induced pluripotent stem cells

BioXcel has entered into a partnership with Takeda Development Center Americas for the repurposing of assets across the gamut of rare diseases

Takeda has licensed exclusive rights to use ImmunoGen’s ADC technology – including ImmunoGen’s new DNA-acting IGN payload agents

Mersana Therapeutics have expanded their ongoing collaboration with Takeda Pharmaceutical to create novel Fleximer antibody-drug conjugate (ADC) drug candidates to include additional oncology-relevant targets

GE Healthcare and Takeda Pharmaceutical have entered into an alliance agreement for research and development in the field of hepatic fibrosis

MacroGenics and Takeda Pharmaceutical announced inking a pharma licensing deal to develop and commercialize four potential product candidates.

Takeda has made a strategic financing investment in BioMotiv and that they have formed a partnership that will leverage the strengths of both organizations to identify and develop pioneering medical innovations.

C4X Discovery biopharma partners by signing a research collaboration agreement with Takeda Cambridge Limited.

MacroGenics and Takeda Pharmaceutical have entered into an option agreement for pharma deal for the development and commercialization of MGD010.

Takeda and University College London will create a biotech partnering on research into muscular disorders, specifically the potential for induced pluripotent (iPS) stem cells to treat muscular dystrophy.